###begin article-title 0
Heterozygous expression of myocilin glaucoma mutants increases secretion of the mutant forms and reduces extracellular processed myocilin
###end article-title 0
###begin p 1
This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Purpose
###end title 2
###begin p 3
###xml 45 50 45 50 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MYOC)</italic>
###xml 91 95 91 95 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MYOC</italic>
Heterozygous mutations in the myocilin gene (MYOC) cause glaucoma by an unknown mechanism. MYOC encodes an extracellular protein of unidentified function that undergoes intracellular endoproteolytic processing in the secretory pathway. It has been described that co-expression of wild-type/mutant myocilin reduces the secretion of the wild-type protein and that single expression of glaucoma myocilin mutants reduces its proteolytic processing. However, the effect of wild-type myocilin on mutant myocilin secretion and how mutant myocilin affects the proteolytic processing of wild-type myocilin have not been investigated. We herein analyze these two issues.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
We modeled the heterozygous state for 4 missense (E323K, R346T, P370L, D380A) and 1 nonsense (Q368X) myocilin mutants by transiently co-expressing each mutant with the wild-type protein in HEK-293T cells. Recombinant mutant and wild-type myocilin in both culture media and cellular fractions were quantified by western immunoblot and densitometry.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
A 24 h transient co-expression of each myocilin mutant with the wild-type protein elicited an augmented secretion of the mutant forms from 1.5 fold (D380A) to 5.4 fold (E323K). Under such conditions, extracellular mutant myocilin represented up to 20% of the total mutant protein. Other than this effect, secreted wild-type myocilin significantly decreased from 2.6 fold (E323K) to 36 fold (Q368X). When myocilin proteolytic processing was enhanced (96 hour co-expression) the extracellular amount of wild-type processed myocilin diminished from approximately 2.1 fold (E323K) to 6.3 fold (P370L). Nonreducing SDS-PAGE indicated that extracellular myocilin resulting from 24 h co-expression of wild-type myocilin and each of the 4 missense mutants forms hetero-oligomers and that glaucoma mutations do not increase the size of myocilin aggregates.
###end p 7
###begin title 8
Conclusions
###end title 8
###begin p 9
Increased extracellular levels of mutant myocilin expressed in heterozygosis may play a relevant role in glaucoma pathogenesis. This effect is likely the result of intracellular mutant/wild-type myocilin hetero-oligomerization.
###end p 9
###begin title 10
INTRODUCTION
###end title 10
###begin p 11
###xml 434 435 434 435 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r1">1</xref>
###xml 489 490 489 490 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r2">2</xref>
###xml 770 771 770 771 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r3">3</xref>
###xml 772 773 772 773 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r4">4</xref>
###xml 816 824 816 824 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MYOCILIN</italic>
###xml 826 830 826 830 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MYOC</italic>
###xml 882 883 882 883 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r5">5</xref>
###xml 999 1000 999 1000 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r6">6</xref>
###xml 1001 1002 1001 1002 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r8">8</xref>
###xml 1018 1022 1018 1022 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MYOC</italic>
###xml 1183 1187 1183 1187 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MYOC</italic>
###xml 1306 1307 1306 1307 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r9">9</xref>
###xml 1308 1310 1308 1310 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r11">11</xref>
###xml 1386 1387 1386 1387 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1650 1652 1650 1652 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r12">12</xref>
###xml 1653 1655 1653 1655 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r13">13</xref>
###xml 1673 1675 1673 1675 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r14">14</xref>
###xml 1780 1781 1780 1781 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r9">9</xref>
###xml 1782 1784 1782 1784 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r15">15</xref>
###xml 1925 1927 1925 1927 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r16">16</xref>
###xml 2014 2015 2014 2015 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 2075 2076 2075 2076 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r9">9</xref>
###xml 2077 2079 2077 2079 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r15">15</xref>
###xml 2189 2191 2189 2191 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r15">15</xref>
###xml 464 470 <span type="species:ncbi:9606">people</span>
###xml 589 597 <span type="species:ncbi:9606">patients</span>
###xml 1151 1159 <span type="species:ncbi:9606">patients</span>
Glaucoma encompasses a heterogeneous group of neurodegenerative diseases as a result of the progressive degeneration of the optic nerve and loss of visual fields. Primary open-angle glaucoma (POAG; OMIM ) is the most frequent type of glaucoma. This disease is the second leading cause of bilateral blindness in developed countries. Indeed, it is estimated that 3-5% of the world population over 40 years of age will develop glaucoma [1], affecting some 60 million people by the year 2010 [2]. Elevated intraocular pressure (IOP) is the main known risk factor of this disease. In most POAG patients increased resistance to the outflow of aqueous humor (AH) in the trabecular meshwork (TM) results in an increment of IOP, causing ganglion cell death in the neural retina [3,4], and subsequent progressive visual loss. MYOCILIN (MYOC; OMIM ) was the first gene identified in glaucoma [5]. Mutations in this gene are mainly confined to exon 3, which encodes the olfactomedin-like domain of the protein [6-8]. Heterozygous MYOC mutations segregate with the disease in a subset of families with autosomal dominant juvenile-onset, and are present in 3-5% of patients with adult-onset POAG. MYOC encodes a 55-57 kDa extracellular glycoprotein of an unknown function that forms homo-oligomers of more than 116 kDa [9-11]. Myocilin shows a modular structure consisting of three domains: 1) the NH2-terminal leucine zipper-like region; 2) a central putative linker domain; and 3) the COOH-terminal olfactomedin-like domain. These domains are encoded by exons 1, 2, and 3, respectively. This protein is relatively abundant in the ciliary body, iris, retina, TM [12,13], and in the AH [14]. It is proteolytically cleaved between amino acids Arg226-Ile227 by calpain II in the lumen of the ER [9,15]. A COOH-terminal proteolytic fragment resulting from cleavage between amino acids Glu214-Leu215 has also been reported in HEBNA 293 cells [16]. The processed COOH-terminal domain is secreted into the culture medium, while the NH2-terminal fragment mainly remains intracellularly retained [9,15]. It has been suggested that this processing could regulate the interaction of myocilin with other proteins [15].
###end p 11
###begin p 12
###xml 182 186 182 186 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MYOC</italic>
###xml 298 300 298 300 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r17">17</xref>
###xml 303 307 303 307 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MYOC</italic>
###xml 366 368 366 368 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r18">18</xref>
###xml 369 371 369 371 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r20">20</xref>
###xml 428 429 428 429 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r9">9</xref>
###xml 430 432 430 432 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r19">19</xref>
###xml 433 435 433 435 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r21">21</xref>
###xml 461 463 461 463 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r22">22</xref>
###xml 464 466 464 466 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r24">24</xref>
###xml 564 566 564 566 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r20">20</xref>
###xml 567 569 567 569 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r25">25</xref>
###xml 570 572 570 572 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r26">26</xref>
###xml 722 724 722 724 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r11">11</xref>
###xml 725 727 725 727 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r19">19</xref>
###xml 728 730 728 730 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r20">20</xref>
###xml 884 888 884 888 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MYOC</italic>
###xml 946 947 946 947 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r9">9</xref>
###xml 444 459 <span type="species:ncbi:10090">transgenic mice</span>
The mechanism by which mutant myocilin causes the glaucoma phenotype remains elusive. Over recent years however, some hypotheses have been formulated to explain the pathogenicity of MYOC mutations. Biochemical and cell biological studies have provided evidence of a gain-of-function disease model [17]. MYOC disease-causing mutations produce misfolded polypeptides [18-20] which show reduced secretion both in cells in culture [9,19,21] and in transgenic mice [22-24]. Non-secreted mutant myocilin could compromise the proteosomal function, leading to cell death [20,25,26]. In addition, it has been reported that wild-type/mutant heteromeric aggregates inhibit the secretion of the wild-type protein in cells in culture [11,19,20]. However, the effect of wild-type myocilin on secretion of the mutant protein has not been investigated. Likewise, it has previously been reported that MYOC mutations reduce the proteolytic processing of myocilin [9], but whether heterozygosis affects the proteolytic processing of myocilin has not been analyzed.
###end p 12
###begin p 13
###xml 97 101 97 101 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MYOC</italic>
In the present study, we investigate the pathogenic mechanism by which heterozygous mutations in MYOC cause glaucoma. We found that co-expression of wild-type and each of 5 different mutant myocilins, lead to a significant increase in the secretion of the mutant myocilins, along with a reduction of the extracellular wild-type proteolytically unprocessed and processed protein, probably by a dominant negative mechanism mediated by heteroaggregation. We speculate that the extracellular presence of mutant myocilin could be a key element in the molecular mechanisms that lead to glaucoma.
###end p 13
###begin title 14
METHODS
###end title 14
###begin title 15
Myocilin constructs
###end title 15
###begin p 16
###xml 131 132 131 132 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r9">9</xref>
###xml 214 215 214 215 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r9">9</xref>
The cDNAs encoding wild-type and glaucoma-causing myocilin mutants were cloned into the EcoRI-BamHI sites of the pcDNA3.1-myc-His [9] and pcDNA3.1-HA-His mammalian expression vectors, used as previously described [9].
###end p 16
###begin title 17
Cell transfections
###end title 17
###begin p 18
###xml 341 342 335 336 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 691 693 685 687 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r15">15</xref>
###xml 871 872 865 866 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 1032 1034 1026 1028 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r15">15</xref>
###xml 4 9 <span type="species:ncbi:9606">human</span>
###xml 223 229 <span type="species:ncbi:9913">bovine</span>
The human embryonic kidney 293T (HEK-293T) cell line was bought from the ATCC (American type Culture Collection, Manassas, VA), and it was maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and antibiotics (Normocin; Invivogen, Tolousse, France) at 37 degreesC, in a fully humidified 5% CO2 atmosphere. Transient plasmid transfections were carried out with 400 ng of total DNA (200 ng of each cDNA construct in co-transfection assays, and 200 ng of the cDNA construct, plus 200 ng of the non-recombinant pcDNA3.1-myc-His vector in single transfection assays) using the Superfect Transfection Reagent (Quiagen, Valencia, CA), as described [15]. The efficiency of transfections was estimated in cells transiently transfected with a cDNA construct encoding GFP by counting the number of GFP-positive cells in a total of 103 cells in four randomly selected areas per dish. The cells were cultured for either 24 or 96 h after transfection to control the degree of myocilin processing [15].
###end p 18
###begin title 19
Western blotting and antibodies
###end title 19
###begin p 20
###xml 697 702 <span type="species:ncbi:10090">mouse</span>
###xml 951 956 <span type="species:ncbi:10090">mouse</span>
###xml 1082 1093 <span type="species:ncbi:3704">horseradish</span>
###xml 1133 1138 <span type="species:ncbi:10090">mouse</span>
Analytical 10% polyacrylamide gel electrophoresis in the presence of SDS was performed using the Mini-PROTEAN III gel electrophoresis system (Bio-Rad, Hercules, CA). For western blot analysis, aliquots of culture medium and cell lysates were treated with loading buffer containing beta-mercaptoethanol, boiled for 5 min, and fractionated by SDS-PAGE. For nonreducing SDS-PAGE, samples were treated with loading buffer without beta-mercaptoethanol, without boiling, and were loaded onto either 8% polyacrylamide gels or 4-15% polyacrylamide gradient gels (Ready Gel, Bio-Rad). Samples were normalized for protein content using the Bradford assay. Alpha-tubulin was detected by western blot using a mouse monoclonal alpha-tubulin antibody (Sigma, St Louis, MO) diluted at 1:5000 as a loading control in cell lysates. Gels were subsequently transferred onto Hybond ECL nitrocellulose membranes (Amersham, Uppsala, Sweden) for immunodetection. Commercial mouse monoclonal anti-myc and anti-HA antibodies (Santa Cruz, Santa Cruz, CA) were used as primary antibodies, diluted at 1:500. A horseradish peroxidase-conjugated antibody against mouse IgG (Pierce Biotechnology, Rockford, IL) was diluted at 1:1000. Chemiluminiscence was performed with Supersignal Dura Western Blot reagents (Pierce). Densitometry for protein band quantitation was performed on scanned films using Quantity One 4.1 analysis software (BioRad) on triplicated independent experiments. The percentage of unprocessed myocilin in either the culture medium or the cellular fraction was calculated as: (extracellular myocilin/total myocilin) x 100 or (intracellular myocilin/total myocilin) x 100, respectively. Total myocilin in each experiment was calculated as the sum of all the myocilin signals in both the culture medium and the cellular fraction. Data were statistically treated by SigmaStat 2.0 software (SPSS Science, Chicago, IL).
###end p 20
###begin title 21
RESULTS
###end title 21
###begin title 22
Analysis of mutant myocilins co-expressed with wild-type myocilin
###end title 22
###begin p 23
###xml 5 9 5 9 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MYOC</italic>
###xml 575 583 575 583 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f1">Figure 1</xref>
###xml 734 736 734 736 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r27">27</xref>
###xml 737 739 737 739 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r29">29</xref>
###xml 823 825 823 825 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r30">30</xref>
###xml 1053 1054 1053 1054 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r5">5</xref>
###xml 1283 1284 1283 1284 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r9">9</xref>
###xml 1285 1287 1285 1287 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r25">25</xref>
###xml 1288 1290 1288 1290 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r31">31</xref>
###xml 1291 1293 1291 1293 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r32">32</xref>
###xml 1414 1415 1414 1415 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r9">9</xref>
###xml 1741 1750 1741 1750 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f2">Figure 2A</xref>
###xml 2125 2136 2125 2136 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f2">Figure 2A,B</xref>
###xml 2439 2450 2439 2450 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f2">Figure 2C,D</xref>
###xml 2874 2883 2874 2883 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f2">Figure 2G</xref>
###xml 95 103 <span type="species:ncbi:9606">patients</span>
###xml 488 496 <span type="species:ncbi:9606">patients</span>
###xml 804 811 <span type="species:ncbi:9606">patient</span>
###xml 1248 1253 <span type="species:ncbi:9606">human</span>
###xml 1386 1391 <span type="species:ncbi:9606">human</span>
Most MYOC mutations identified today in adult-onset and autosomal dominant juvenile-onset POAG patients are present in the heterozygous state. To study the mechanism by which these mutations lead to glaucoma, we have used a cellular model of heterozygosis. The heterozygous state was simulated by transiently co-expressing in HEK-293T cells, wild-type-HA myocilin, and each of 4 different missense (E323K, R346T, P370L, and D380A) or 1 nonsense (Q368X) mutant myocilins found in glaucoma patients. Mutant proteins were tagged at their COOH-terminal end with the myc-epitope (Figure 1). Three of the missense mutations were selected because they were considered representative of autosomal dominant glaucoma (E323K, P370L, and D380A) [27-29]. The fourth missense mutation (R346T), identified in a Spanish patient with POAG [30] was considered as an example of a myocilin variant involved in non-Mendelian glaucoma, whereas the nonsense mutation Q368X has been found in both autosomic dominant juvenile-onset glaucoma and non-Mendelian cases of glaucoma [5].The HEK-293T cell line was chosen because is well characterized, allows easy expression of recombinant proteins and has been previously used as a cellular model to study different recombinant human proteins including myocilin [9,25,31,32]. The experiments were replicated in COS-1 cells as well as in a cell line derived from the human ciliary muscle (hCM) [9] (data not shown). Initially as a control, we performed a single transfection of HEK-293T cells with the cDNAs encoding wild-type myocilin and each of the 5 pathogenic mutations. By western blot we analyzed the distribution of the mutant proteins in both the culture medium and the cellular fraction 24 h after transfection (Figure 2A). We observed that while 62% of total wild-type myocilin was present intracellularly, more than 80% of each mutant myocilin accumulated intracellularly. Interestingly enough, small amounts of mutant myocilins (ranging from 0.4 to 14.3% of total mutant protein for Q368X and D380A mutations, respectively) were present in the culture medium, mainly as full-length molecules (Figure 2A,B). Next, we studied the effect of wild-type myocilin on the secretion of mutant myocilins. When the cDNAs encoding each mutant myocilin were transiently co-transfected with equal amounts of the cDNA encoding the wild-type protein, the presence of extracellular mutant myocilins increased significantly (Figure 2C,D; red bars). The percentage of missense myocilins in the culture medium ranged from about 7 to 22% for mutants P370L and D380A, respectively. In contrast, the extracellular level of truncated myocilin Q368X was very low (<1.5%), even in co-expression with wild-type myocilin. The fold increase of extracellular full-length mutant myocilins in heterozygosis ranged from 1.5 to 5.4, for mutants D380A and E323K, respectively (Figure 2G).
###end p 23
###begin p 24
Scheme of wild-type and mutant myocilin cDNA constructs used in this study. The localization of different domains and epitopes of myocilin is indicated by rectangles filled with different patterns. Numbers correspond to positions in the myocilin amino acid sequence.
###end p 24
###begin p 25
###xml 290 291 290 291 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 562 563 562 563 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 593 594 593 594 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E</bold>
###xml 968 969 968 969 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 969 970 969 970 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">,</italic>
###xml 970 971 970 971 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</bold>
###xml 976 977 976 977 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F</bold>
###xml 1094 1095 1094 1095 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 1121 1122 1121 1122 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">,</italic>
###xml 1122 1123 1122 1123 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 1142 1143 1142 1143 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E</bold>
###xml 1921 1922 1921 1922 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 1927 1928 1927 1928 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</bold>
###xml 1930 1931 1930 1931 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G</bold>
###xml 1942 1943 1942 1943 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F</bold>
###xml 1945 1946 1945 1946 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">H</bold>
###xml 2002 2003 2002 2003 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G</bold>
Wild-type/mutant myocilin co-expression significantly increases the amount of extracellular mutant myocilin compared to single mutant expression. HEK-293T cells were transiently transfected with 200 ng of cDNA constructs encoding 5 different myocilin-myc mutants or wild-type myocilin-myc (A). To model the heterozygous expression of myocilin mutants, cells were co-transfected with 200 ng of cDNAs encoding each mutant myocilin-myc and 200 ng of a cDNA construct encoding wild-type myocilin-HA. Twenty-four hours after transfection, the recombinant mutant-myc (C) and wild-type-HA myocilins (E) in both the culture medium and cells were analyzed by 10% polyacrylamide SDS-PAGE and western blot using either an anti-myc or an anti-HA monoclonal antibody, respectively. Arrows and arrowheads indicate the position of full-length myocilin (55 kDa), and the 35 kDa processed olfactomedin-containing fragment, respectively. Molecular weight markers are shown on the left. B,D and F: Densitometric quantitation of full-length myocilin and its processed olfactomedin-containing fragment, detected in A (bars with oblique lines),C (solid bars), and E (dotted bars). Red bars represent the percentage of extracellular unprocessed full-length or truncated Q368X myocilin (extracellular myocilin/total myocilin), blue bars correspond to the extracellular olfactomedin-containing fragment (extracellular 35 kDa myocilin/total myocilin), and yellow bars represent intracellular full-length myocilin or the truncated Q368X form (intracellular myocilin/total myocilin), respectively. Total myocilin in each experiment was calculated as the sum of all the myocilin signals in both the culture medium and the cellular fraction. Error bars represent the S.E. of triplicate experiments. To facilitate the comparison of the percentage of extracellular unprocessed full-length or truncated Q368X myocilin, the corresponding bars form panels B and D (G) or panel F (H) are represented together. Numbers above bars in panel G indicate the fold-increase of full-length myocilin in cotransfections versus single transfections. Statistical significance as compared with full-length wild-type myocilin, was calculated using the Student's test. The asterisk indicates a p<0.05, the double asterisk indicates a p<0.01 and the triple asterisk indicates a p<0.001.
###end p 25
###begin p 26
###xml 107 118 107 118 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f2">Figure 2E,F</xref>
###xml 324 333 324 333 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f2">Figure 2H</xref>
###xml 523 532 523 532 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f2">Figure 2H</xref>
In the same experiments we also analyzed how mutant myocilins affected secretion of the wild-type protein (Figure 2E,F). The percentage of wild-type myocilin in the culture medium fell significantly (p<0.05) from 35% (control single transfection) to about 9-14% when it was co-expressed with mutants E323K, R346T, or D380A (Figure 2H). The co-expression with mutants Q368X and P370L resulted in a remarkable reduction of the extracellular wild-type protein to approximately 1% (36 fold) and 3.4% (10.5 fold), respectively (Figure 2H).
###end p 26
###begin p 27
###xml 145 153 145 153 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f2">Figure 2</xref>
###xml 420 422 420 422 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r33">33</xref>
###xml 465 473 465 473 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f3">Figure 3</xref>
###xml 549 557 549 557 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f3">Figure 3</xref>
The proportion of myc- and HA-tagged wild-type myocilin in the culture medium and cellular fractions was similar in single and co-transfections (Figure 2; wild-type lanes), indicating that co-expression does not affect the distribution of the protein. We confirmed that the expression levels of wild-type and mutant myocilin were similar in co-transfected cells by western blot analysis using an anti-myocilin antibody [33] that recognizes both types of molecules (Figure 3). We did not detect the expression of endogenous myocilin by western blot (Figure 3), which allowed us to rule out any significant interference of the endogenous protein with the different recombinant myocilins expressed in these cells.
###end p 27
###begin p 28
###xml 79 80 79 80 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 735 736 735 736 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 789 790 789 790 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
Co-expression of wild-type and mutant myocilin does not alter myocilin levels. A: HEK-293T cells were transiently transfected with 200 ng of cDNAs constructs encoding either mutant myocilins E323K or Q368X. These cells were also co-transfected with 200 ng of a cDNA construct encoding wild-type myocilin-HA and 200 ng of either cDNA encoding mutant myocilin-myc E323K or Q368X. Ninety-six hours after transfection, total recombinant myocilin in cell lysates were analyzed by 10% polyacrylamide SDS-PAGE and western blot using the anti-myocilin polyclonal antibody R14T. The black and white arrows indicate the position of full-length myocilin and truncated Q368X myocilin, respectively. Molecular weight markers are shown on the left. B: densitometric quantitation of myocilin detected in A. Error bars represent the S.E. of triplicate experiments.
###end p 28
###begin title 29
Analysis of the proteolytic processing of myocilin in heterozygosis
###end title 29
###begin p 30
###xml 271 273 271 273 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r15">15</xref>
###xml 503 514 503 514 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f4">Figure 4A,B</xref>
###xml 575 576 575 576 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r9">9</xref>
###xml 753 764 753 764 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f4">Figure 4A,B</xref>
###xml 860 871 860 871 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f4">Figure 4A,B</xref>
###xml 964 975 964 975 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f4">Figure 4C,D</xref>
###xml 1094 1103 1094 1103 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f4">Figure 4G</xref>
In the next step of the study we analyzed how heterozygous expression affected the processing of both mutant and wild-type myocilin. Transiently transfected cells were cultured for 96 h to increase the extracellular presence of the 35 kDa processed fragment of myocilin [15]. In control single transfections 40% of total wild-type myocilin corresponded to the extracellular processed fragment, 5% to the extracellular full-length protein, and the remaining 55% to the intracellular full-length protein (Figure 4A,B). In contrast, and in accordance with our previous results [9], the percentage of all extracellular mutant COOH-terminal fragments dropped significantly to values varying from about 0.6% (P370L) to 14.5% (D380A) of total mutant myocilin (Figure 4A,B; blue bars). As expected the 35 kDa fragment was not detected in the truncated myocilin Q368X (Figure 4A,B). In co-transfections, all the mutant olfactomedin-containing fragments increased slightly (Figure 4C,D), between 1.3 and 1.8 times compared to single-transfections, although the differences were not significant (p>0.05) (Figure 4G).
###end p 30
###begin p 31
###xml 281 282 281 282 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 486 487 486 487 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 492 493 492 493 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E</bold>
###xml 956 957 956 957 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 957 958 957 958 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">,</italic>
###xml 958 959 958 959 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</bold>
###xml 964 965 964 965 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F</bold>
###xml 1082 1083 1082 1083 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 1109 1110 1109 1110 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">,</italic>
###xml 1110 1111 1110 1111 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 1129 1130 1129 1130 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E</bold>
###xml 1812 1813 1812 1813 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 1818 1819 1818 1819 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</bold>
###xml 1821 1822 1821 1822 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G</bold>
###xml 1833 1834 1833 1834 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F</bold>
###xml 1836 1837 1836 1837 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">H</bold>
Wild-type/mutant myocilin co-expression reduces significantly the extracellular wild-type olfactomedin cleaved fragment of myocilin. HEK-293T cells were transiently transfected with 200 ng of cDNA constructs encoding the 5 different myocilin-myc mutants or wild-type myocilin-myc (A). To model the heterozygous expression of myocilin mutants cells were co-transfected with 200 ng of cDNAs encoding each mutant myocilin-myc and 200 ng of a cDNA construct encoding wild-type myocilin-HA (C and E). Ninety-six hours after transfection, recombinant mutant and wild-type myocilins-myc in the culture medium and in cell lysates were analyzed by 10% polyacrylamide SDS-PAGE and western blot using either an anti-myc or a anti-HA monoclonal antibody, respectively. Arrows and arrowheads indicate the position of full-length myocilin (55 kDa), and the 35 kDa processed olfactomedin-containing fragment, respectively. Molecular weight markers are shown on the left. B,D and F: Densitometric quantitation of full-length myocilin and its processed olfactomedin-containing fragment, detected in A (bars with oblique lines),C (solid bars) and E (dotted bars). Red bars represent the percentage of extracellular full-length or truncated Q368X myocilin (extracellular myocilin/total myocilin), blue bars correspond to the extracellular olfactomedin-containing fragment (extracellular 35 kDa myocilin/total myocilin), and yellow bars represent intracellular full-length myocilin or the truncated Q368X form (intracellular myocilin/total myocilin), respectively. The total myocilin in each experiment was calculated as the sum of all the myocilin signals in both the culture medium and the cellular fraction. To facilitate the comparison of the percentage of secreted mutant olfactomedin domain the corresponding bars form panels B and D (G) or panel F (H) are represented together. Error bars represent the S.E. of triplicate experiments. Statistical significance as compared with the COOH-terminal fragment of wild type myocilin was calculated using the Student's test. The triple asterisk indicates a p<0.001.
###end p 31
###begin p 32
###xml 194 205 194 205 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f4">Figure 4E,F</xref>
###xml 412 421 412 421 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f4">Figure 4H</xref>
###xml 533 542 533 542 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f4">Figure 4C</xref>
###xml 664 673 664 673 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f4">Figure 4E</xref>
The heterozygous expression of wild-type myocilin with each of the 5 mutants for 96 h also produced a remarkable drop in the proportion of the extracellular wild-type 35 kDa processed fragment (Figure 4E,F; blue bars), from 40% of total wild-type myocilin (control) to 20% for the D380A mutant, and to 6%-11% for the other 4 mutants. These values represent a fold reduction ranging from 2 (D380A) to 6.3 (P370L; Figure 4H). Again, and as expected, the COOH-terminal myocilin fragment was not present in the truncated myocilin Q368X (Figure 4C), although the processed COOH-terminal peptide arising from the wild-type counterpart was detected with the HA antibody (Figure 4E). Cell viability and cell lysis at the end of these experiments were determined by the MTT and LDH assays, respectively. No significant effects on these two parameters were observed (data not shown).
###end p 32
###begin title 33
Aggregation of mutant myocilins co-expressed with wild-type myocilin
###end title 33
###begin p 34
###xml 467 478 467 478 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f5">Figure 5A-C</xref>
###xml 611 620 611 620 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f2">Figure 2A</xref>
###xml 713 715 713 715 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r10">10</xref>
###xml 716 718 716 718 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r34">34</xref>
###xml 719 721 719 721 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r35">35</xref>
###xml 1091 1102 1091 1102 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f5">Figure 5A,B</xref>
###xml 1266 1277 1266 1277 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f5">Figure 5D,E</xref>
###xml 1393 1402 1393 1402 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f5">Figure 5A</xref>
###xml 1410 1419 1410 1419 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f5">Figure 5C</xref>
###xml 1460 1468 1460 1468 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f2">Figure 2</xref>
We reasoned that if glaucoma mutations increased the molecular size of myocilin aggregates, then they could obstruct AH outflow and hence raise IOP. Therefore, we analyzed by nonreducing SDS-PAGE and western blot whether heterozygous expression of myocilin glaucoma mutants affected myocilin self-aggregation. Culture media from cells expressing myocilin for 24 h showed a regular size pattern of myocilin aggregates, consisting of several bands larger than 118 kDa (Figure 5A-C; wild-type lanes), where the lower band probably corresponds to a myocilin dimer. Aggregates disappeared under reducing conditions (Figure 2A), showing that they are maintained by disulphide bonds in accordance with previous reports [10,34,35]. Extracellular myocilin aggregates resulting from transient co-transfection of HEK-293T cells with equal amounts (200 ng) of cDNA constructs encoding wild-type and each of the 4 missense myocilin mutants showed the same pattern and were recognized by both anti-HA and anti-myc antibodies, indicating that they correspond to wild-type/mutant myocilin heteroaggregates (Figure 5A,B). To facilitate the comparison of the molecular size of myocilin aggregates, sample volumes were corrected by normalizing the total amount of myocilin per sample (Figure 5D,E). In addition, the level of the 4 missense mutant myocilins increased in co-expression with the wild-type protein (Figure 5A versus Figure 5C) agreeing with the results presented in Figure 2. These data indicate that mutant/wild-type myocilin heteroaggregation increases the presence of extracellular mutant myocilin and also show that glaucoma mutations do not increase the molecular size of either myocilin homo- or heteroaggregates (wild-type/mutant). Aggregates resulting from the co-expression of Q368X and wild-type myocilin were only recognized by the anti-HA antibody, indicating that they are composed of only the wild-type protein, and suggesting that the olfactomedin domain could be required for correct formation of intermolecular disulphide bonds.
###end p 34
###begin p 35
###xml 210 218 210 218 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f2">Figure 2</xref>
###xml 494 495 494 495 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 551 552 551 552 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 637 638 637 638 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 699 700 699 700 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 702 703 702 703 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 708 709 708 709 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 847 848 846 847 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 850 851 849 850 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</bold>
###xml 857 858 856 857 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 860 861 859 860 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E</bold>
Aggregation of wild-type and mutant myocilins co-expressed for 24 h. HEK-293T cells were transiently transfected with cDNA constructs encoding 5 different myocilin mutants or wild-type myocilin as described in Figure 2. Myocilin aggregates secreted after 24 h of expression were analyzed by nonreducing SDS-PAGE (4-15% gradient polyacrylamide) and were detected by western blot. The culture media from co-transfections were analyzed using either an anti-myc antibody to detect mutant myocilin (A), or an anti-HA antibody to detect wild-type myocilin (B). Control single transfections were analyzed using an anti-myc monoclonal antibody (C). Molecular weight markers are shown on the right of panels A, B and C. To facilitate the comparison of the molecular size of myocilin aggregates different volumes (1 to 50 mul) of culture medium from panels B (D) and C (E) were loaded into gels and analyzed by nonreducing SDS-PAGE (8% polyacrylamide).
###end p 35
###begin title 36
DISCUSSION
###end title 36
###begin title 37
Heterozygous expression of myocilin mutants
###end title 37
###begin p 38
###xml 329 333 329 333 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MYOC</italic>
###xml 751 752 751 752 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r9">9</xref>
###xml 753 755 753 755 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r18">18</xref>
###xml 756 758 756 758 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r19">19</xref>
###xml 759 761 759 761 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r21">21</xref>
###xml 762 764 762 764 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r24">24</xref>
###xml 839 841 839 841 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r22">22</xref>
###xml 1231 1233 1219 1221 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r36">36</xref>
###xml 1328 1330 1316 1318 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r11">11</xref>
###xml 1331 1333 1319 1321 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r19">19</xref>
###xml 1334 1336 1322 1324 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r20">20</xref>
###xml 1970 1978 1952 1960 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f6">Figure 6</xref>
###xml 2517 2528 2499 2510 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f2">Figure 2C,D</xref>
###xml 2934 2936 2916 2918 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r33">33</xref>
###xml 2937 2939 2919 2921 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r37">37</xref>
###xml 2940 2942 2922 2924 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r38">38</xref>
###xml 3890 3892 3872 3874 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r11">11</xref>
###xml 3893 3895 3875 3877 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r19">19</xref>
###xml 3929 3931 3911 3913 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r20">20</xref>
###xml 4318 4320 4300 4302 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r39">39</xref>
###xml 789 804 <span type="species:ncbi:10090">transgenic mice</span>
###xml 2639 2647 <span type="species:ncbi:9606">patients</span>
###xml 2824 2832 <span type="species:ncbi:9606">patients</span>
###xml 4107 4112 <span type="species:ncbi:9606">human</span>
The mechanism by which heterozygous glaucoma mutant myocilins cause either autosomal dominant glaucoma or predispose to non-Mendelian POAG is currently not well understood. Some hypotheses have been proposed over recent years in an attempt to explain myocilin glaucoma pathogenesis. Most of these hypotheses do not consider that MYOC mutations involved in glaucoma are usually present in heterozygosis. To gain insight into this issue, we have set up a cellular model of heterozygous expression of wild-type/mutant myocilin in HEK-293T cells. Different groups have consistently shown that pathogenic mutant myocilins transiently expressed in homozygosis accumulate intracellularly in cells in culture, probably as a consequence of protein misfolding [9,18,19,21,24]. Similarly, homozygous transgenic mice expressing mutant myocilin Y423H [22] show reduced secretion of myocilin into the AH, although the animals do not develop glaucoma. Some studies have also shown that certain myocilin mutants, including E323K and D380A, are poorly secreted when expressed alone at 37 degreesC, and that expressing mutant myocilins at a lower temperature (30 degreesC), a condition known to facilitate protein folding, enhances their secretion [36]. A few reports have described that mutant myocilin reduces extracellular wild-type myocilin [11,19,20]. However, to the best of our knowledge the effect of wild-type myocilin on mutant myocilin secretion and how mutant myocilin affects the proteolytic processing of wild-type myocilin have not been investigated. In accordance with some of the previous studies, we observed low secretion of the 5 different myocilin mutants transiently expressed in single transfection (homozygosis) at 37 degreesC. Nevertheless, transient co-expression (heterozygosis) of each of these mutants with the wild-type protein increased the intracellular retention of wild-type myocilin and simultaneously raised the extracellular concentration of mutants (Figure 6; points 1 and 2). Heteroaggregation could explain how mutant and wild type myocilin affect each other's secretion. The variations observed in the extracellular amount of each myocilin mutant might be due to specific structural defects, which could affect formation of wild-type/mutant heteroaggregates. It is noteworthy that extracellular missense mutant myocilins represented a significant fraction of the total mutant protein expressed in this model of heterozygosis, ranging from 8% to 20% for P370L and D380A mutations, respectively (Figure 2C,D). These findings suggest that the AH and extracellular matrix of the outflow pathway in heterozygous glaucoma patients might contain significant amounts of mutant myocilin, higher than previously thought, forming part of heteroaggregates (wild-type/mutant). The extracellular mutant myocilin in patients could be secreted by different tissues such as the ciliary muscle, ciliary epithelium, and TM cells [33,37,38]. Therefore, it can be also speculated that blocking the secretion of mutant myocilin could be of therapeutic value. It is interesting to note that secretion and processing of myocilin mutations associated with Mendelian cases of glaucoma did not differed significantly from those found in non-Mendelian glaucoma, indicating that other factors should determine the type of inheritance. Our data also suggest that the amount of wild-type myocilin present in the AH could be considerably reduced in heterozygosis (between 2.6 and 10.5 times, for the wild-type myocilin co-expressed with mutants E323K and P370L, respectively). The largest reduction of extracellular wild-type myocilin was produced by the nonsense mutation Q368X. In accordance with our results it has been reported that co-transfection of COS-7 and TM cells with a cDNA encoding wild-type myocilin and increasing amounts of a Q368X cDNA reduced the extracellular wild-type protein [11,19]. Similarly, Joe and co-workers [20] reported that wild-type myocilin-GFP adenovirally co-expressed in TM cells with 4 missense mutant myocilins (G364V, K423E, Y437H, and I477N) mainly accumulated in lysates of human TM cells but was also present in the culture medium. However, another study did not detect wild-type myocilin in the culture medium of TM cells adenovirally co-expressing wild-type and Q368X-GFP myocilin [39]. This discrepancy could be due to different experimental conditions and/or to lower detection sensitivity.
###end p 38
###begin p 39
###xml 833 835 833 835 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r15">15</xref>
###xml 919 921 919 921 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r15">15</xref>
Model of the secretion and proteolytic processing of wild-type/mutant myocilin heteroaggregates. Heteroaggregation takes place in the lumen of the ER. For simplicity the diagram shows a heterodimer but the aggregates are composed of multiple myocilin monomers (indicated by dots in the heteroaggregate) linked by disulphide bonds (short black lines in the heterodimer). According to this model heteroaggregation has three major effects: 1) increases the retention of wild-type myocilin in the ER via a dominant negative effect (DNE); 2) increases secretion of mutant myocilin along with a reduction of extracellular wild-type myocilin, and 3) reduces the amount of extracellular wild-type myocilin (olfactomedin fragment) under conditions known to increase the proteolytic cleavage of myocilin by calpain II such as 96 h of culture [15]. The N-terminal fragment that arises after the cleavage mainly remains in the ER [15]. A possible gain of function (GOF) of mutant myocilin (both full-length and cleaved olfactomedin fragment) that could contribute to glaucoma pathogenesis is also indicated. The leucine zipper (yellow), linker (red), and olfactomedin (blue) domains of myocilin are also indicated in the heterodimer. The ray indicates mutant myocilin. Question marks indicate a hypothetical dominant negative effect and/or gain of function of the mutant protein.
###end p 39
###begin title 40
Molecular mechanisms of myocilin-associated glaucoma
###end title 40
###begin p 41
###xml 245 247 245 247 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r11">11</xref>
###xml 248 250 248 250 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r19">19</xref>
###xml 251 253 251 253 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r20">20</xref>
###xml 355 359 355 359 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MYOC</italic>
###xml 527 531 527 531 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MYOC</italic>
###xml 547 549 547 549 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r17">17</xref>
###xml 668 670 668 670 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r40">40</xref>
###xml 1036 1038 1036 1038 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r21">21</xref>
###xml 1394 1396 1394 1396 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r21">21</xref>
###xml 1456 1458 1456 1458 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r41">41</xref>
###xml 1763 1767 1763 1767 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MYOC</italic>
###xml 1793 1795 1793 1795 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r22">22</xref>
###xml 1884 1886 1884 1886 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r42">42</xref>
###xml 1913 1915 1913 1915 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r23">23</xref>
###xml 2267 2269 2267 2269 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r43">43</xref>
###xml 337 345 <span type="species:ncbi:9606">patients</span>
###xml 541 545 <span type="species:ncbi:10090">mice</span>
###xml 878 886 <span type="species:ncbi:9606">patients</span>
###xml 1177 1185 <span type="species:ncbi:9606">patients</span>
###xml 1446 1454 <span type="species:ncbi:9606">patients</span>
###xml 1652 1657 <span type="species:ncbi:10090">mouse</span>
###xml 1702 1707 <span type="species:ncbi:9606">human</span>
###xml 1776 1791 <span type="species:ncbi:10090">transgenic mice</span>
###xml 1835 1840 <span type="species:ncbi:10090">mouse</span>
###xml 1861 1866 <span type="species:ncbi:10090">mouse</span>
###xml 1891 1896 <span type="species:ncbi:9606">human</span>
###xml 1957 1962 <span type="species:ncbi:10090">mouse</span>
###xml 2026 2032 <span type="species:ncbi:9606">humans</span>
###xml 2241 2246 <span type="species:ncbi:10090">mouse</span>
Different mechanisms could contribute to the disease phenotype in myocilin-associated glaucoma. In accordance with our results, and as already mentioned, it has been reported that mutant myocilin inhibits the secretion of the wild-type protein [11,19,20]. These data suggest that wild-type myocilin could be absent in the AH of glaucoma patients carrying MYOC mutations. However, reduction or absence of the extracellular normal protein neither explains the apparently normal ocular phenotype in both hemizygous and homozygous MYOC-knockout mice [17], nor why mutations such as K423E, which causes glaucoma in heterozygotes, do not produce the disease in homozygotes [40]. From our data we can hypothesize that the presence of extracellular mutant myocilin could be required to produce the disease phenotype, offering an explanation for the lack of glaucoma in K423E homozygous patients. According to this idea, it has been reported that this mutation is not secreted when expressed alone in transiently transfected COS-7 or HTM cells [21], indicating that it could be extracellularly absent in homozygous subjects. However, it might be present extracellularly in heterozygous patients, where it is co-expressed with wild-type myocilin. Likewise, our hypothesis also explains why mutation T377M, which indeed is detected extracellularly in single transient transfections of COS-7 or HTM cells [21], is associated with glaucoma in homozygous POAG patients [41]. Data obtained from some animal models of glaucoma support the role of extracellular mutant myocilin in the pathogenesis of glaucoma. In that sense, it has been reported that non-secretion of mouse mutant myocilin Y423H, which corresponds to human mutation Y437H, is not sufficient to cause glaucoma in MYOC-knockin transgenic mice [22]. However, the phenotype of transgenic mouse expressing the same mouse mutant myocilin [42] or human myocilin Y437H [23] in the presence of endogenous wild-type mouse myocilin, show phenotypic features similar to those of POAG in humans (i.e. moderate elevation of IOP, loss of approximately 20% of retinal ganglion cells in the peripheral retina, and axonal degeneration in the optic nerve). The reasons for the phenotypic differences in these mouse models are unclear [43].
###end p 41
###begin p 42
###xml 301 309 301 309 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f6">Figure 6</xref>
###xml 713 714 713 714 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r9">9</xref>
###xml 1019 1030 1019 1030 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f3">Figure 3B,D</xref>
###xml 1720 1728 1720 1728 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f6">Figure 6</xref>
###xml 2200 2204 2200 2204 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MYOC</italic>
###xml 2335 2339 2335 2339 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MYOC</italic>
###xml 2384 2386 2384 2386 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r17">17</xref>
###xml 2387 2389 2387 2389 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r20">20</xref>
###xml 2427 2429 2427 2429 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r11">11</xref>
###xml 2430 2432 2430 2432 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r40">40</xref>
###xml 2433 2435 2433 2435 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r44">44</xref>
###xml 2605 2606 2605 2606 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r9">9</xref>
###xml 2607 2609 2607 2609 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r18">18</xref>
###xml 2610 2612 2610 2612 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r19">19</xref>
###xml 2613 2615 2613 2615 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r32">32</xref>
###xml 2616 2618 2616 2618 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r45">45</xref>
###xml 2661 2663 2661 2663 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r26">26</xref>
###xml 2701 2703 2701 2703 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r20">20</xref>
###xml 2747 2748 2747 2748 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r9">9</xref>
###xml 2854 2856 2854 2856 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r46">46</xref>
###xml 2942 2944 2942 2944 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r21">21</xref>
###xml 2169 2177 <span type="species:ncbi:9606">patients</span>
Interestingly enough, in this study we have also found for the first time that the extracellular presence of mutant myocilin is associated with a reduction in the amount of extracellular processed wild-type myocilin (olfactomedin domain) by around 2 to 6 times after 96 h in culture. This phenomenon (Figure 6; point 3) could also be due to a dominant negative effect resulting from heteroaggregation and might contribute to the pathogenic mechanism that leads to IOP rising and glaucoma. Dominant negative effects are often caused by mutations in multimeric proteins, and imply that the mutant protein loses its native function and interferes with that of the wild-type protein. According to our previous study [9] we found that the four pathogenic myocilins inhibited the proteolytic processing with varying efficiency. Again we observed that mutation P370L, which produces the most severe glaucoma phenotype, also elicited the most potent endoproteolytic cleavage reduction, in both single and double transfections (Figure 3B,D; blue bars). However, both the actual molecular mechanism by which reduction of the processed myocilin may lead to glaucoma and the physiologic signal(s) that trigger myocilin processing remain to be elucidated. Our hypothesis proposes that the extracellular presence of mutant myocilin is the primary key factor in myocilin-associated glaucoma, which as mentioned previously, is associated with the reduction of both extracellular wild-type myocilin, either as a full-length or proteolytically cleaved protein, and mutant myocilin processing. One can also speculate that a hypothetical gain of function of both extracellular heteroaggregates and mutant olfactomedin-containing fragments (Figure 6) might alter myocilin turnover and/or interactions with other macromolecules, leading to myocilin accumulation over time in the extracellular matrix of tissues of the eye such as the TM and the uveoscleral outflow pathway. Our results do not support an obstruction of the AH outflow by an increase in the molecular size of myocilin aggregates. Further studies are required to determine whether the AH and extracellular matrix from glaucoma patients carrying heterozygous MYOC mutations contains myocilin heteroaggregates. According to these ideas it has also been claimed that disease-causing mutations on MYOC likely act by a gain of function mechanism [17,20], and/or a dominant negative effect [11,40,44]. Biochemical studies have indicated that the gain of function might be related to several phenomena including: intracellular accumulation in the ER of mutant proteins [9,18,19,32,45], Russell bodies formation and apoptosis [26], cytotoxicity induced by ER stress [20], reduction of its proteolytic processing [9], exposure of a cryptic signaling site that causes mislocalization of the mutant protein to peroxisomes [46], and abnormal interaction(s) between myocilin and ECM and/or cell surface proteins [21]. Our hypothesis does not exclude other proposed mechanisms of myocilin associated glaucoma, instead it complement the current view of glaucoma pathogenesis.
###end p 42
###begin p 43
Regarding the genotype-phenotype relationship, we did not find a definitive correlation between the extracellular levels of the 3 missense myocilins and the phenotype, indicating that other unknown factors, such a possible mutation-specific gain of function, could contribute to the phenotype. The Q368X myocilin mutation represents a particular case in glaucoma pathogenesis since it produces a truncate protein which lacks the COOH-terminal half of the olfactomedin-like domain. Whether this difference could explain, at least in part, why Q368X is associated with a milder phenotype and low penetrance remains to be investigated.
###end p 43
###begin p 44
###xml 442 450 <span type="species:ncbi:9606">patients</span>
In summary, our cellular model of heterozygosis shows that co-expression of wild-type and mutant myocilins increases significantly the presence of extracellular mutant molecules and reduces the amount of either extracellular full-length or processed wild-type myocilin. These data suggests that the abnormal protein could be present through heteroaggregates in the AH and extracellular matrix of the TM and uveoscleral AH outflow of glaucoma patients, playing pivotal roles in the pathogenesis of glaucoma.
###end p 44
###begin title 45
ACKNOWLEDGMENTS
###end title 45
###begin p 46
###xml 507 512 <span type="species:ncbi:9689">Lions</span>
This work was supported in part by research grants from the Regional Ministry of Health and the Regional Ministry of Science and Technology of the Board of the Communities of "Castilla-La Mancha", "Fondo de Investigaciones Sanitarias" and "Instituto de Salud Carlos III" (GCS-2006_C/12; PAI-05-002 and PCI08-0036; PI052494, and RD07/0062/0014 to J. E.); and by National Institute of Health grants (EY04873; EY00785 for core facilities, to M.C.-P.) and from Research to Prevent Blindness and The Connecticut Lions Foundation (to M.C.-P.). F. Martinez-Redondo is recipient of a fellowship from the Regional Ministry of Education and Science of the Board of the Communities of "Castilla-La Mancha".
###end p 46
###begin title 47
REFERENCES
###end title 47
###begin article-title 48
Study of central retinal ganglion cell loss in experimental glaucoma in monkey eyes.
###end article-title 48
###begin article-title 49
###xml 14 20 <span type="species:ncbi:9606">people</span>
The number of people with glaucoma worldwide in 2010 and 2020.
###end article-title 49
###begin article-title 50
Myocilin and glaucoma: facts and ideas.
###end article-title 50
###begin article-title 51
Recent developments in understanding the pathophysiology of elevated intraocular pressure.
###end article-title 51
###begin article-title 52
Identification of a gene that causes primary open angle glaucoma.
###end article-title 52
###begin article-title 53
###xml 56 61 <span type="species:ncbi:9606">human</span>
Cloning and characterization of subtracted cDNAs from a human ciliary body library encoding TIGR, a protein involved in juvenile open angle glaucoma with homology to myosin and olfactomedin.
###end article-title 53
###begin article-title 54
###xml 48 56 <span type="species:ncbi:9606">patients</span>
Analysis of myocilin mutations in 1703 glaucoma patients from five different populations.
###end article-title 54
###begin article-title 55
Genetic dissection of myocilin glaucoma.
###end article-title 55
###begin article-title 56
Myocilin mutations causing glaucoma inhibit the intracellular endoproteolytic cleavage of myocilin between amino acids Arg226 and Ile227.
###end article-title 56
###begin article-title 57
Gene structure and properties of TIGR, an olfactomedin-related glycoprotein cloned from glucocorticoid-induced trabecular meshwork cells.
###end article-title 57
###begin article-title 58
Intracellular sequestration of hetero-oligomers formed by wild-type and glaucomacausing myocilin mutants.
###end article-title 58
###begin article-title 59
###xml 133 138 <span type="species:ncbi:9606">human</span>
Isolation and characterization of cell-specific cDNA clones from a subtractive library of the ocular ciliary body of a single normal human donor: transcription and synthesis of plasma proteins.
###end article-title 59
###begin article-title 60
Recurrent mutations in a single exon encoding the evolutionarily conserved olfactomedin-homology domain of TIGR in familial open-angle glaucoma.
###end article-title 60
###begin article-title 61
The Presence and Properties of Myocilin in the Aqueous Humor.
###end article-title 61
###begin article-title 62
Characterization of the intracellular proteolytic cleavage of myocilin and identification of calpain II as a myocilin-processing protease.
###end article-title 62
###begin article-title 63
Perfusion with the olfactomedin domain of myocilin does not affect outflow facility.
###end article-title 63
###begin article-title 64
###xml 62 67 <span type="species:ncbi:9606">Human</span>
Targeted Disruption of the Myocilin Gene (Myoc) Suggests that Human Glaucoma-Causing Mutations Are Gain of Function.
###end article-title 64
###begin article-title 65
Inefficient processing of an olfactomedin-deficient myocilin mutant: potential physiological relevance to glaucoma.
###end article-title 65
###begin article-title 66
Non-secretion of mutant proteins of the glaucoma gene myocilin in cultured trabecular meshwork cells and in aqueous humor.
###end article-title 66
###begin article-title 67
###xml 88 93 <span type="species:ncbi:9606">human</span>
Accumulation of mutant myocilins in ER leads to ER stress and potential cytotoxicity in human trabecular meshwork cells.
###end article-title 67
###begin article-title 68
Functional analysis of the glaucoma-causing TIGR/myocilin protein: integrity of amino-terminal coiled-coil regions and olfactomedin homology domain is essential for extracellular adhesion and secretion.
###end article-title 68
###begin article-title 69
Mutant myocilin nonsecretion in vivo is not sufficient to cause glaucoma.
###end article-title 69
###begin article-title 70
###xml 0 15 <span type="species:ncbi:10090">Transgenic mice</span>
###xml 51 56 <span type="species:ncbi:9606">human</span>
Transgenic mice expressing the Tyr437His mutant of human myocilin protein develop glaucoma.
###end article-title 70
###begin article-title 71
###xml 89 104 <span type="species:ncbi:10090">transgenic mice</span>
Overexpression and properties of wild-type and Tyr437His mutated myocilin in the eyes of transgenic mice.
###end article-title 71
###begin article-title 72
Reversal of mutant myocilin non-secretion and cell killing: implications for glaucoma.
###end article-title 72
###begin article-title 73
Aggregated myocilin induces russell bodies and causes apoptosis: implications for the pathogenesis of myocilin-caused primary open-angle glaucoma.
###end article-title 73
###begin article-title 74
Richards JE. GLC1A mutations point to regions of potential functional importance on the TIGR/MYOC protein.
###end article-title 74
###begin article-title 75
Farrar GJ. A novel Asp380Ala mutation in the GLC1A/myocilin gene in a family with juvenile onset primary open angle glaucoma.
###end article-title 75
###begin article-title 76
###xml 62 70 <span type="species:ncbi:9606">patients</span>
Lopez- Martinez F.Escribano J. MYOC gene mutations in Spanish patients with autosomal dominant primary open-angle glaucoma: a founder effect in southeast Spain.
###end article-title 76
###begin article-title 77
###xml 0 4 <span type="species:ncbi:289672">Coca</span>
###xml 81 89 <span type="species:ncbi:9606">patients</span>
Coca- Prados M.Escribano J. Role of MYOC and OPTN sequence variations in Spanish patients with Primary Open-Angle Glaucoma.
###end article-title 77
###begin article-title 78
Age-dependent prevalence of mutations at the GLC1A locus in primary open-angle glaucoma.
###end article-title 78
###begin article-title 79
A cellular assay distinguishes normal and mutant TIGR/myocilin protein.
###end article-title 79
###begin article-title 80
###xml 86 91 <span type="species:ncbi:9606">human</span>
Expression of the TIGR gene in the iris, ciliary body, and trabecular meshwork of the human eye.
###end article-title 80
###begin article-title 81
Characterization of myocilin-myocilin interactions.
###end article-title 81
###begin article-title 82
In vitro and in vivo characterization of disulfide bond use in myocilin complex formation.
###end article-title 82
###begin article-title 83
Temperature sensitive secretion of mutant myocilins.
###end article-title 83
###begin article-title 84
Cellular pharmacology and molecular biology of the trabecular meshwork inducible glucocorticoid response gene product.
###end article-title 84
###begin article-title 85
###xml 36 41 <span type="species:ncbi:9606">human</span>
Localization of MYOC transcripts in human eye and optic nerve by in situ hybridization.
###end article-title 85
###begin article-title 86
Expression of wild-type and truncated myocilins in trabecular meshwork cells: their subcellular localizations and cytotoxicities.
###end article-title 86
###begin article-title 87
Homozygotes carrying an autosomal dominant TIGR mutation do not manifest glaucoma.
###end article-title 87
###begin article-title 88
Myocilin variations and familial glaucoma in Taxiarchis, a small Greek village.
###end article-title 88
###begin article-title 89
###xml 22 27 <span type="species:ncbi:10090">mouse</span>
###xml 68 83 <span type="species:ncbi:10090">transgenic mice</span>
Expression of mutated mouse myocilin induces open-angle glaucoma in transgenic mice.
###end article-title 89
###begin article-title 90
###xml 39 46 <span type="species:ncbi:9606">patient</span>
Molecular and clinical evaluation of a patient hemizygous for TIGR/MYOC.
###end article-title 90
###begin article-title 91
Altered secretion of a TIGR/MYOC mutant lacking the olfactomedin domain.
###end article-title 91
###begin article-title 92
Glaucoma-causing myocilin mutants require the Peroxisomal targeting signal-1 receptor (PTS1R) to elevate intraocular pressure.
###end article-title 92

